Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8965 Safety and PK in Healthy Participants
NCT06502379Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD8965, sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and serious adverse events at 8 weeks and Maximum observed drug concentration. Started Aug 2024; status: completed.
02
Drugs
AZD8965
Beyond the preview
Go deeper on NCT06502379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502379.